Table 3.
Ongoing invasive non-pharmacological clinical trials registered at the World Health Organization (WHO) International Clinical Trials Research Platform (ICTRP) for people with Huntington’s disease (HD)
| Registration ID | Trial name | Intervention | Mechanism of Action | Population | Comparison | Main outcome | Study design | Esimated Enrolment | Sponsor | Location |
| ISRCTN52651778 | TRIDENT | Foetal stem cell transplant | Stem cell therapy | Early stage HD | Usal care | Safety at 4 weeks | Randomized, open label, controlled, parallel trial | 30 | Cardiff University | UK (single centre) |
| NCT02728115 | SAVE-DH | Cellavita | Stem cell therapy | HD | None | Safety at 5 years | Non-randomized, open label, uncontrolled, parallel trial | 6 | Azidus Brasil | Brazil (single centre) |
| NCT03252535 | ADORE-HD | Cellavita | Stem cell therapy | HD | Placebo | Efficacy at 120 days | Randomized, double-blind, placebo-controlled, parallel trial | 35 | Azidus Brasil | Brazil (single centre) |
| NCT03297177 | – | Autologous stem/stromal cells | Autologous stem/stromal cell injection | HD, AD, PD, CBD, MS | None | Safety at 5 years | Single group, open-label trial | 300 | Healeon Medical Inc, Global Alliance for Regenerative Medicine, Regeneris Medical | USA and Honduras (multi-centre) |
| NCT02535884 | HD-DBS | GP DBS | Deep brain stimulation | Moderate HD with chorea | Sham intervention | Efficacy at 12 months | Randomized, double-blind, sham-controlled, parallel trial | 50 | Heinrich-Heine University, KKS Netzwerk, Medtronic, The George Institute, EHDN, CHDI Foundation, Inc. | Austria, France Germany, Switzerland (multi centre) |
| NCT01834053 | BMACHC | Bone Marrow Derived MNC transplant | Bone marrow transplant | HD with chorea | None | Cognitive and behavioural effects at 6 months | Single group, open-label trial | 50 | Chaitanya Hospital, Pune | India (single centre) |
| NCT02263430 | – | GP DBS | Deep brain stimulation | HD with chorea | Sham stimulation | Efficacy at 12 months | Randomized, double-blind, placebo-controlled, parallel trial | 8 | Beijing Pins Medical Co., Ltd, Beijing Tiantan Hospital | China (single centre) |
| NCT02252380 | – | Magnetic Resonance Guided Focused Ultrasound | Extracranial stereotactic radioablation | HD, ET, HT, PD, WD, dystonia, TD, or orofacial dyskinesias | None | Adverse events after the procedure | Single group, open-label trial | 10 | InSightec | Canada (single centre) |
AD, Alzheimer’s disease, CBD; Corticobasal Degeneration; DBS, deep brain stimulation; ET, Essential Tremor; GP, Globus pallidus; HT, Holmes Tremor; MNC, mononuclear cells; MS, Multiple Sclerosis; PD, Parkinson’s disease; TD, Tardive dyskinesia; WD, Wilson’s disease.